{"entity":{"id":"nct06590246","kind":"trial","name":"A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)","aka":[],"tldr":"A phase 1/2 trial of Armored and GPC3-targeted autologous CAR T-cell in hepatocellular carcinoma, run by Shanghai AbelZeta Ltd., now recruiting.","summary":"A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC) is a phase 1/2 interventional study registered as NCT06590246 by Shanghai AbelZeta Ltd., with 121 participants planned, started 2024-09-30 and due to reach its primary completion in 2030-04-30. Interventions recorded: Armored and GPC3-targeted autologous CAR T-cell.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06590246","url":"https://clinicaltrials.gov/study/NCT06590246"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["shanghai-abelzeta"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06590246","phase":"1/2","setting":"Phase I/II Clinical Study of Armored and GPC3-targeted Autologous Chimeric Antigen Receptor (CAR) T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","sponsor":"Shanghai AbelZeta Ltd.","enrolled":121,"outcomes":[]},"route":"/trials/nct06590246/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"company":[{"id":"shanghai-abelzeta","kind":"company","name":"Shanghai AbelZeta","route":"/companies/shanghai-abelzeta/"}]}}